Nina Cosdon

Prior infection is not enough: COVID-19 vaccination reduces the risk of reinfection by 50%.

An HIV-positive woman in her 60s has recovered from a simultaneous heart and kidney transplant.

Last weekend, the World Health Organization declared the monkeypox viral outbreaks a Public Health Emergency of the International Concern (PHEIC).

This Israeli study found 3 and 4 doses of Pfizer-BioNTech bolstered antibody titers in adults 60 and older.

The CDC is advising clinicians to test for parechovirus in infants exhibiting fever, sepsis-like syndrome, or signs of neurological impairment.

As monkeypox cases increase, investigators are turning to smallpox antivirals.

2 patients died of Marburg virus in the southern Ashanti region of Ghana. Nearly 100 close contacts are now under observation for the infectious disease, which is a cousin of the Ebola virus.

The BA.2 COVID-19 variant maintained the mutations necessary for viral entry, but developed an increased ability to evade neutralization by monoclonal antibodies.

In children 5-11 years old, 2 doses of the Pfizer-BioNTech COVID-19 vaccine were moderately effective against documented, symptomatic Omicron infection.

Predicted time to breakthrough infection after mRNA vaccination was significantly longer than the time to breakthrough infection after natural infection or after viral vector vaccination.

Investigators found potentially infectious monkeypox virus DNA in saliva and semen.

Children and adolescents previously infected with COVID-19 or MIS-C demonstrated insufficient antibody titers and neutralization capability against the Omicron variant.

At 12 months after COVID-19 infection, anti-SARS-CoV-2 spike receptor-binding domain IgG persisted in all age groups.

Receiving a COVID-19 booster vaccine significantly reduced Omicron infections among National Basketball Association (NBA) players and staff.

Hospitalization rates increased significantly after sepsis, with 11.9% of survivors rehospitalized for recurrent sepsis, and 56.6% receiving outpatient anti-infective treatment.

An active viral reservoir of COVID-19 spike protein was detected in 65% of patients with post-acute sequelae of COVID-19.

The overall sensitivity of rapid antigen tests was 63%. However, the tests had a limited ability to detect asymptomatic Omicron infections.

Omicron significantly diminishes the protective abilities of both natural immunity and vaccine-granted immunity.

From December 2020-September 2021, approximately 27 million COVID-19 infections, 1.6 million hospitalizations, and 235000 deaths were prevented by vaccination.

Treatment with the novel antiviral sabizabulin reduced COVID-19 death by 55.2% in hospitalized patients with moderate to severe disease.

Dr. Arlene Sena and her team are working to develop a syphilis vaccine, “But we need to know what’s circulating worldwide first.”

This first study of the UK’s ongoing monkeypox outbreak reported the clinical and demographic features of 54 confirmed cases.

All studies included in this research found a correlation between area-level racial prejudice and adverse health outcomes among racial and ethnic minority populations.

Antibody levels decline in individuals with hybrid immunity similarly to vaccinated individuals, meaning all people need a booster vaccine to protect against future, potentially severe, infection.

Maternal mortalities increased 33.3% during the COVID-19 pandemic, while overall deaths increased 22%. Excess deaths were most prevalent in Hispanic and Black mothers.

Many people who self-report as symptomatic for COVID-19 neglect to get tested, largely citing not knowing where to go for a test as the reason.

After an all-day meeting, the FDA’s Vaccine and Related Biological Products Advisory Committee (VRBPAC) voted 90% YES to recommend this fall’s COVID-19 booster doses target Omicron.

Sanofi and GSK, Pfizer-BioNTech, and Moderna are all working on booster candidates specifically designed to neutralize Omicron and its subvariants.

The World Health Organization did not declare monkeypox a global health emergency, instead calling it an “evolving health threat” that requires continued monitoring.

Dr. Heather Platt discusses the process of developing V116, a pneumococcal vaccine that targets the serotypes most prevalent in those 65 years and older.